[go: up one dir, main page]

WO1999006577A3 - Agent permettant d'exprimer et de mettre en evidence la presence d'un polypeptide de fusion comprenant un epitope hpol et un polypeptide - Google Patents

Agent permettant d'exprimer et de mettre en evidence la presence d'un polypeptide de fusion comprenant un epitope hpol et un polypeptide Download PDF

Info

Publication number
WO1999006577A3
WO1999006577A3 PCT/DE1998/002221 DE9802221W WO9906577A3 WO 1999006577 A3 WO1999006577 A3 WO 1999006577A3 DE 9802221 W DE9802221 W DE 9802221W WO 9906577 A3 WO9906577 A3 WO 9906577A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
hpol
epitope
expressing
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1998/002221
Other languages
German (de)
English (en)
Other versions
WO1999006577A2 (fr
Inventor
Karl-Werner Knopf
Uwe Schreiner
Reiner Strick
Jutta Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Bayer AG
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ, Bayer AG filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to JP2000505317A priority Critical patent/JP2001512026A/ja
Priority to EP98948711A priority patent/EP1002112A1/fr
Publication of WO1999006577A2 publication Critical patent/WO1999006577A2/fr
Publication of WO1999006577A3 publication Critical patent/WO1999006577A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

L'invention concerne un vecteur d'expression codant un polypeptide de fusion comprenant un épitope HPOL et un polypeptide. L'invention concerne en outre un anticorps dirigé à l'encontre d'un polypeptide de fusion de ce type, son utilisation, ainsi qu'un kit approprié à l'expression et à la mise en évidence du polypeptide de fusion.
PCT/DE1998/002221 1997-08-01 1998-07-29 Agent permettant d'exprimer et de mettre en evidence la presence d'un polypeptide de fusion comprenant un epitope hpol et un polypeptide Ceased WO1999006577A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000505317A JP2001512026A (ja) 1997-08-01 1998-07-29 Ｈｐｏｌエピトープとポリペプチドとの融合ポリペプチドの発現及び検出用薬剤
EP98948711A EP1002112A1 (fr) 1997-08-01 1998-07-29 Agent permettant d'exprimer et de mettre en evidence la presence d'un polypeptide de fusion comprenant un epitope hpol et un polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19733389.3 1997-08-01
DE19733389A DE19733389C2 (de) 1997-08-01 1997-08-01 Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids

Publications (2)

Publication Number Publication Date
WO1999006577A2 WO1999006577A2 (fr) 1999-02-11
WO1999006577A3 true WO1999006577A3 (fr) 1999-04-22

Family

ID=7837751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1998/002221 Ceased WO1999006577A2 (fr) 1997-08-01 1998-07-29 Agent permettant d'exprimer et de mettre en evidence la presence d'un polypeptide de fusion comprenant un epitope hpol et un polypeptide

Country Status (5)

Country Link
EP (1) EP1002112A1 (fr)
JP (1) JP2001512026A (fr)
DE (1) DE19733389C2 (fr)
IT (1) ITMI981685A1 (fr)
WO (1) WO1999006577A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513295A (ja) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド １２３種類のヒト分泌タンパク質

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120639A (en) * 1989-04-03 1992-06-09 E. R. Squibb & Sons, Inc. Selective inhibition of dna polymerase
WO1997007132A1 (fr) * 1995-08-15 1997-02-27 Commonwealth Scientific And Industrial Research Organisation Systeme de marquage par epitopes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120639A (en) * 1989-04-03 1992-06-09 E. R. Squibb & Sons, Inc. Selective inhibition of dna polymerase
WO1997007132A1 (fr) * 1995-08-15 1997-02-27 Commonwealth Scientific And Industrial Research Organisation Systeme de marquage par epitopes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KNOPF C.W.: "Nucleotide sequence of the DNA polymerase gene of herpes simplex virus type 1 strain Angelotti", NUCLEIC ACIDS RESEARCH, vol. 14, no. 20, 1986, pages 8225 - 826, XP002093668 *
STRICK R. ET AL.: "Epitope mapping and functional characterization of monoclonal antibodies specific for Herpes simplex virus type I DNA polymerase", INTERVIROLOGY, vol. 40, no. 1, July 1997 (1997-07-01), pages 41 - 49, XP002093667 *

Also Published As

Publication number Publication date
DE19733389A1 (de) 1999-02-11
JP2001512026A (ja) 2001-08-21
ITMI981685A1 (it) 2000-01-21
ITMI981685A0 (it) 1998-07-21
DE19733389C2 (de) 1999-08-19
EP1002112A1 (fr) 2000-05-24
WO1999006577A2 (fr) 1999-02-11

Similar Documents

Publication Publication Date Title
AU1747697A (en) Multi-pieced, portable projection dome and method of assembling the same
EP0623297A3 (fr) Parapluie.
WO1995007994A3 (fr) Vecteurs composes d'alphavirus recombinants
EP0831097A3 (fr) Dihydrate D d'olanzapine
WO1996017072A3 (fr) Vecteurs d'alphavirus de recombinaison
NZ315809A (en) Opiate tetrapeptides with a tyr (or 2',6'-dimethyl tyr) at one terminus and an optionally substituted amino at the other terminus
EP0645217A3 (fr) Marteau non-destructif.
EP0624420A3 (fr) Soudage par friction.
EP0628373A3 (fr) Soudage par friction.
EP0627232A3 (fr) Raccord rapide.
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
FR2704924B1 (fr) Vanne pyrotechnique.
AU2764997A (en) Udp-(n)-acetyl-alpha-d-galactosamine:polypeptide (n)-acetylgalactosaminyltransferase, galnac-t3
HUP0103152A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
AU6775894A (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
WO1998057983A3 (fr) Proteine de mammifere de type facteur de croissance nerveuse
CY2467B1 (en) Activation pin.
NO963487D0 (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
EP0669396A4 (fr) Nouveau polypeptide et adn codant pour celui-ci.
EP0624783A3 (fr) Dispositif d'essai de lentilles.
GB2326712B (en) Colour devoloping method,enzyme immunoassay using the colour developing method,and immunochromatography incorporating the enzyme immunoassay
EP0627276A3 (fr) Jonction par friction.
AU2547995A (en) Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof
WO1999006577A3 (fr) Agent permettant d'exprimer et de mettre en evidence la presence d'un polypeptide de fusion comprenant un epitope hpol et un polypeptide
ZA935880B (en) Simplified fully antomatic umbrella

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998948711

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998948711

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09463840

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998948711

Country of ref document: EP